Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Organovo Holdings Inc ONVO

Healthcare Biotechnology
Organovo Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ONVO)

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

GlobeNewswire 6 days ago

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

GlobeNewswire 13 days ago

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

GlobeNewswire July 16, 2024

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

GlobeNewswire May 21, 2024

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

GlobeNewswire May 14, 2024

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

GlobeNewswire May 8, 2024

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

GlobeNewswire April 15, 2024

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress

GlobeNewswire January 25, 2024

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

GlobeNewswire January 9, 2024
View More News ››

Opinion & Analysis (NDAQ:ONVO)

3D printing is a manufacturing game-changer

Richard (Rick) Mills November 15, 2019

Cutting-edge devices and diagnostics deliver drugs and profits: Cantor Fitzgerald's Caroline Corner

George S. Mack July 31, 2015

The Calandra Report: More biotech, Bitterroot, CTIX, BCRX, CUR and more

Thom Calandra January 14, 2014
View More Opinion ››

Bullboard Posts (NDAQ:ONVO)

Organovo Holdings, Inc. (ONVO): Advancing Clinical Developme

http://beyondspx.com/2024/08/01/organovo-holdings-inc-onvo-advancing-clinical-development-of-fxr314-and-building-high-fidelity-3d-tissue...
MikeTester - August 2, 2024

Organovo Highlights FXR314 Near Term Value Catalysts at Jone

News; $ONVO Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for...
whytestocks - July 16, 2024

Why Organovo Stock Is Up Today | Benzinga

BREAKING NEWS: $ONVO Why Organovo Stock Is Up Today | BenzingaOrganovo Holdings, Inc. (NASDAQ:ONVO) shares are trading higher Monday...
whytestocks - April 15, 2024

ONVO....The Perfect Storm?

Go ahead ....I dare ya ; ) A positive News Released this a.m with an S-1 filed and Effective EDGAR Entity Landing Page (sec.gov)
Iseneschal - April 15, 2024

adding more shares here today

using dollar cost averaging for this one,so glta.
coolfooldumbguy - May 31, 2019

it's a buy today for me

at the 75 cent mark,so glta.
coolfooldumbguy - May 30, 2019
View more Bullboard ››

Silvercorp Metals Inc.

Silvercorp Metals Inc.

Silvercorp is a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability and ...
View More »